Sign inJoin waitlistJoin the waitlist

Stacy Cooper

Program Director · Johns Hopkins University School of Medicine

Credentials: · · ·

History

Johns Hopkins University School of Medicine
Present
Clinical Center at the National Institutes of Health
Present

Pediatric Hematology-Oncology
Johns Hopkins University School of Medicine
2011–2012
Pediatrics
2008–2011
SUNY Upstate Medical University Coll of Med
2004–2008

Research

Treatment of pediatric acute lymphoblastic leukemia
Review · Pediatric Clinics of North America · 2015 · First of 2 authors · 235 citations
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults
Blood · 2023 · 57 citations
Universal premedication and therapeutic drug monitoring for asparaginase-based therapy prevents infusion-associated acute adverse events and drug substitutions
Pediatric Blood & Cancer · 2019 · First of 6 authors · 53 citations

David Cooke
5 papers
EF
Emily Frosch
5 papers
EB
Eric Balighian
5 papers
Jenna Rossoff
5 papers
Michelle Hermiston
5 papers
PB
Patrick Brown
5 papers
William Golden
5 papers
Amy Moskop
4 papers
Christine Phillips
4 papers
KC
Kevin Curran
4 papers
Liora Schultz
4 papers
Muna Qayed
4 papers

Clinical trials

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2020–2028
A Pilot Study of Allopurinol As A Modifier of 6-MP Metabolism in Pediatric ALL
Principal investigator · Completed · Early phase 1
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2014–2020
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2028
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2025–2030